CYP1B1 and metabolic dysfunction-associated steatotic liver disease: NAFLD—a chronic liver disorder characterized by hepatocellular lipid accumulation [60]—can be ameliorated by PSP through suppression of CYP1B1-mediated lipid phagocytosis and enhanced hepatic α-ketoglutarate synthesis via glutamine metabolism, indicating its utility in NAFLD management.